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ReviewGlossary
Allodynia: pain due to a stimulus that does not normally evoke pain.
Dicer and Drosha: two key enzymes involved in miRNA biogenesis. Drosha is a
ribonuclease III enzyme present in the nucleus and involved in the generation
of pre-miRNA from the primary miRNA transcript. Dicer is an endoribonuclease
also of the ribonuclease III family that cleaves pre-miRNA into short, double-
stranded RNA fragments of 20–25 bp in length.
Hyperalgesia: increased pain from a noxious stimulus (i.e., a stimulus that
normally evokes pain).
Long ncRNAs (lncRNAs): endogenous ncRNA sequences longer than 200
nucleotides.
miRNAs: short endogenous ncRNAs that usually range between 20 and 24
nucleotides in length. miRNAs are ubiquitously expressed across all tissue
types and play an important role in development and function. miRNAs bind to
mRNA sequences based on seed-region sequence complementarity and lead
to reduced target protein expression because of either mRNA degradation or
translational repression.
miRNA-#-5p and miRNA-#-3p: mature miRNAs are designated -5p or -3p
depending on the arm of pre-miRNA from which they are generated (e.g., miR-
124-3p and miR-124-5p). It is common to observe deregulation of one specific
form in disease models.
Nociceptor: neurons that respond to nociceptive (painful) stimuli.
Noncoding RNAs (ncRNAs): transcribed RNAs that do not encode a protein.
ncRNAs range from a few nucleotides to kilobases in length and are classified
with different names depending on size and function.Although noncoding RNAs (ncRNAs) were initially con-
sidered to be transcriptional byproducts, recent techno-
logical advances have led to a steady increase in our
understanding of their importance in gene regulation
and disease pathogenesis. In keeping with these devel-
opments, pain research is also experiencing rapid
growth in the investigation of links between ncRNAs
and pathological pain. Although the initial focus was on
analyzing expression and dysregulation of candidate
miRNAs, elucidation of other ncRNAs and ncRNA-medi-
ated functional mechanisms in pain modulation has just
commenced. Here we review the major ncRNA literature
available to date with respect to pain modulation and
discuss tools and opportunities available for testing the
impact of other types of ncRNA on pain.
Emerging roles of ncRNAs in pain
Pain perception is a subjective experience that is charac-
terized not only by sensory determinants but also by
factors modulating cognitive and emotional processing,
such as previous experience, setting, gender, affective
states, and learning. These factors make it difficult to
define and treat pain, particularly chronic pain. Acute pain
usually lasts as long as the stimulus is applied and resolves
quickly, thereby serving as a natural defense mechanism
to caution and protect an individual from potential dam-
age. By contrast, chronic pain can outlast the period of
initial injury or damage (e.g., on inflammation or nerve
damage) and increases the disease burden, worsens quali-
ty of life, and calls for clinical intervention.
Although a vast amount of knowledge has been gained
on peripheral and central mechanisms of chronic pain,
translation thereof into clinical treatments has remained
difficult. A major causal factor has been attributed to the
large number of mediators and signaling pathways that
have been discovered to contribute to chronic pain and to
the high degree of functional redundancy between them.
Thus, targeting single molecules via pharmacological in-
tervention is unlikely to suffice in treating chronic pain.1471-4914/
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emergence of ncRNAs (see Glossary) as key post-transcrip-
tional regulators with the ability to modify the expression
of a multitude of mRNA targets and the corresponding
proteins. Among ncRNAs, miRNAs are the best studied
and are now recognized to be important for diverse facets of
the nervous system, ranging from development to disease
pathology [1–4]. Unique ncRNA expression signatures are
believed not only to characterize specific types of cells, but
also to be indicative of particular disease states. Thus,
ncRNAs can not only serve as diagnostic and prognostic
markers, but may also reveal key insights into transcrip-
tional and translational mechanisms in chronic pain
states. One of the most important reasons for their thera-
peutic promise is their ability to modulate the expression
and stability of a vast number of gene transcripts; thus, by
manipulating the expression and function of a single
ncRNA in vivo, it might be possible to target severalP element-induced wimpy testis (PIWI)-interacting RNAs (piRNAs): endogen-
ous ncRNAs ranging between 26 and 31 nucleotides in length that interact with
-PIWI proteins to mediate epigenetic and post-translational gene silencing.
Precursor miRNA (pre-miRNA): hairpin-shaped double-stranded RNA struc-
tures resulting from the action of a microprocessor complex containing the
ribonuclease III enzyme Drosha in the cell nucleus.
Seed sequence: the nucleotide sequence from the second to the ninth position
from the 50 end of a mature miRNA is known as the seed sequence and has
been shown to be important for miRNA–mRNA functional pairing.
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studies on mRNA transcripts regulated by miRNAs in
nociceptive pathways have also revealed that a single
miRNA can downregulate both excitatory and inhibitory
targets in nociceptive neurons, potentially leading to the
regulation of both pronociceptive and antinociceptive
aspects and rendering prediction of net functional out-
comes difficult. A few recently published in vivo studies
do indicate that, despite this largesse of potential mRNA
targets, specific functional roles can indeed be attributed to
some miRNAs, paving the way for translational develop-
ments.
Here we first review the relative abundance of studies
that have elucidated the expression of miRNAs and the
dysregulation thereof in nociceptive pathways, then elab-
orate on tools and technologies for functional analyses of
miRNAs and discuss how these were used to uncover
functional roles of miRNAs in some studies. Finally, we
discuss the functional implications of ncRNAs other than
miRNAs, such as long ncRNAs (lncRNAs) and P element-
induced wimpy testis (PIWI) protein-interacting RNAs
(piRNAs), in nociceptive pathways and include a discus-
sion of opportunities and challenges in this field.
Expression and dysregulation of miRNAs in animal
models of chronic pain
Although numerous tools have been developed to study the
expression and differential regulation of ncRNAs [5,6],
microarray-based or PCR-based methods are widely used
in pain research. High-throughput methods such as micro-
array profiling or deep sequencing are used to understand
global ncRNA expression levels and quantitative real-time
PCR (qRT-PCR) is used to quantify the differential regu-
lation of a candidate ncRNA. In situ hybridization (ISH) is
another widely used method that provides the cell-specific
expression profile of a given ncRNA. Northern blotting is
still considered the gold standard in ncRNA research but
its use has been limited in pain studies because of inherent
technical limitations [5].
miRNAs in peripheral sensory neurons
Peripheral sensory neurons, with their soma in the dorsal
root ganglion (DRG) and their axon terminals in the skin
and other organs, serve as the first site of the transduction
of physicochemical noxious stimuli (such as heat, cold,
pressure, or acid) into a change in neuronal membrane
potentials and the transmission of this nociceptive informa-
tion to the central nervous system (CNS). Neuropathic pain
represents a largely intractable form of chronic pain. Sever-
al groups have employed preclinical neuropathic mouse and
rat models such as spinal nerve ligation (SNL), chronic
constriction injury (CCI), and sciatic nerve injury to study
miRNA deregulation in neuropathic pain states. miRNA
deregulation has also been reported in other chronic pain
conditions that are mimicked by mouse models of inflam-
matory pain [e.g., involving peripheral hind-paw inflamma-
tion with Freund’s Complete Adjuvant (CFA) or
carrageenan] or models of early hypersensitivity evoked
by peripheral formalin injection. Both of these models in-
volve the persistent delivery of ongoing nociceptive inputs
from the periphery into the CNS (reviewed in [7,8]).438Various forms of cancer are accompanied by debilitating
chronic pain and both peripheral and central mechanisms
play a crucial role in the mediation of tumor-mediated
pain. However, to date only one study has addressed
regulation of the miRNA repertoire in tumor-mediated
pain conditions [9] (Table 1). It has been reported that,
in the DRGs of a bone metastasis-associated pain model, 57
miRNAs are deregulated [9]. These miRNAs are involved
in the maintenance, but not in the development phase, of
tumor-mediated hyperalgesia. By interfering with miRNA
expression in DRGs in vivo, this study reported pronocicep-
tive effects of miR-1a-3p, miR-34c-5p, and miR-370-3p, and
a novel miRNA–mRNA functional pair (miR-1a-3p and
Clcn3) was identified in the context of cancer pain. Although
this study provides first proof of principle for manipulating
miRNAs in the treatment of cancer pain, further studies are
needed to obtain clearer insights into the network regula-
tion of miRNAs and target genes and to develop miRNAs as
new targets for the treatment of cancer pain.
Certain miRNAs have been reported to be deregulated
across different pain models. For instance, the miRNA-183
family comprising miR-183, miR-182, and miR-96 is
claimed to be expressed in a sensory organ-specific manner
by several groups and its consistent downregulation has
been reported in ipsilateral DRGs in several neuropathic
and inflammatory pain models [10–15]. miR-143 is
expressed in DRGs and its expression has been reported
to be decreased in ipsilateral DRGs following peripheral
CFA-induced inflammatory pain or sciatic nerve transec-
tion-induced neuropathic pain [16]. However, there are
very few commonalities between miRNAs regulated across
different pain models, suggesting disorder-specific involve-
ment of miRNAs and making it difficult to infer common
miRNA regulators in nociceptive modulation. For instance,
several miRNAs such as miR-34 family members, miR-33a,
miR-369-5p, miR-142-5p, and miR-218 have been shown to
be strongly downregulated following neuropathic pain in-
duction [17] but are strongly upregulated following bone
metastatic pain induction in ipsilateral DRGs [9]. Further-
more, neither the sensory organ-specific miRNA cluster
nor the CNS-specific miRNA miR-124 is dysregulated in
bone-metastatic conditions in peripheral sensory neurons
[9]. Also across different models of neuropathic pain, there
are contrasting reports about the regulation of a given
miRNA. For instance, miR-1 has been shown to be down-
regulated in the DRG on partial nerve injury [18] and
paradoxically upregulated in a sciatic nerve axotomy
(SNA) model [18]. Therefore, miRNA expression profiling
results should be evaluated carefully with respect to the
time point tested and the method and platform used, to
exclude technical influences or restrictions imposed by
experimental design on the results obtained while drawing
biologically relevant conclusions from the data. It should
be noted that miRNAs expressed in non-neuronal cells can
also influence sensory neurons and pain perception (Box 1).
miRNAs in the spinal cord
The spinal cord dorsal horn (SDH) is the location of the
secondary neurons that receive nociceptive stimuli from
peripheral sensory neurons and transmit them to the
brain along ascending pathways. Changes in the gene
Table 1. miRNA regulation in diverse regions of the somatosensory nociceptive pathway in different chronic pain conditions
miRNA studieda Pain model Tissue studied Time point
studied
Observed expression
change
Refs
miRNAs in peripheral nervous system
Neuropathic pain
miRNA-183 cluster (comprising
miR-183, miR-182, and miR-96)
SNL in mice DRGs 14 days Decreased [10]
SNC in mice Sciatic nerves 4 and 7 days
following SNI
Decreased [79]
miRNA-183 SNL in rat DRGs 7 and 14 days Decreased [15]
miRNA-21 SNT in rat DRGs 7 days Increased [60]
SNR in rat DRGs 4 days Increased [80]
SNC in mice Sciatic nerves 4 and 7 days Increased [79]
miR-7a SNL in rat Ipsilateral lumbar
5 (L5) DRGs
14 days Decreased [58]
miR-96 CCI in rat Ipsilateral DRG Day 7–21 Decreased [62]
miR-143 SNT in mice Ipsilateral DRG 6 days Decreased [16]
miR-1, miR-16, miR-206 SNA in mice Ipsilateral DRG Day 1–3 Increased [18]
miR-125b-5p, miR-30d-5p,
miR-379-5p
SNL in rats genetically
segregated to sense high
or low neuropathic pain
Ipsilateral DRG 3 days Differentially regulated [81]
Inflammatory pain
miR-183, miR-124a CFA-induced inflammatory
muscle pain model in rat
Ipsilateral
trigeminal ganglion
4 h to 4 days Decreased [82]
miR-134 CFA-induced inflammatory
pain model in rat
Ipsilateral DRGs Days 1–14 Decreased from 1 to 7 days
and increased at 14 days
[83]
miR-183 cluster, miR-146a Knee-joint osteoarthritis
(OA) model in rat
Ipsilateral lumbar
DRGs and SDH
2, 4, and 8
weeks
Decreased [84,85]
miR-143 CFA model in mice Ipsilateral DRGs 2 days Decreased [16]
miR-1, miR-16, miR-206 CFA model in mice Ipsilateral DRGs 12 h to 7 days Decreased [18]
Cancer-associated pain
miR-1a-3p, miR-544-3p,
miR-34c-5p, and 23 other
miRNAs
Bone metastasis model
in mouse
Ipsilateral DRGs 8 days Increased [9]
miR-370-3p, miR-483-3p,
miR-291b-5p, and 28 other
miRNAs
Bone metastasis model
in mouse
Ipsilateral DRGs 8 days Decreased [9]
miRNAs in spinal cord
miR-137, miR-181a, miR-219-2-3p,
and 247 other miRNAs
Traumatic SCI in rat SDH 4 h and 1 and
7 days
Differential regulation [86]
miRNA-203 Bilateral CCI in rat SDH 14 days Decreased [87]
miR-103 SNL in rat SDH Not available Decreased [34]
miR-1 SNA in mice SDH Days 1–3 Decreased [18]
miR-1, miR-124, miR-129-1,
miR-129-2
SCI in rat Whole spinal cord 4 and 14 days Decreased [88]
miR-223 SCI in mice Whole spinal cord 6 h to 7 days Increased from 6 h to day 3 [89]
miR-124a SCI in mice Whole spinal cord 6 h to 7 days Decreased from day 1 to 7 [89]
miR-21 SCI in mice Whole spinal cord Days 4–35 Increased at day 35 [90]
miR-146a OA in rat Lumbar SDH 2 and 4 weeks Decreased [84]
miR-124a Intraplantar application of
formalin or interleukin-1b
(IL-1b) (an inflammatory
mediator) in mice
SDH or in spinal
microglia
Hours 1–48 Decreased from 1 to 24 h,
basal levels at 48 h
[35,57]
miR-1, miR-16, miR-206 CFA in mice SDH Days 1–7 Increased [18]
miRNAs in brain regions involved in pain
miR-155, miR-223 Model of facial inflammatory
pain in mouse
Prefrontal cortex Day 3 Increased [23]
miR-200b, miR-429 PNL model of neuropathic
pain in mice
Nucleus
accumbens
Day 7 after sciatic
nerve ligation
was found
Decreased [24]
miR-146a, miR-34c, miR-125b-5p,
miR-1, and others
CCI in rat Hippocampus Days 7 and 14 Decreased [91]
let-7 family members, miR-103,
and others
CCI in rat Hippocampus Days 7 and 14 Increased [91]
Abbreviations: SNL, spinal nerve ligation; SNC, sciatic nerve crush; SNI, spared nerve injury; SNT, sciatic nerve transaction; SNR, sciatic nerve resection; CCI, chronic
constriction injury; SNA, sciatic nerve axotomy; DRG, dorsal root ganglion; OA, osteoarthritis; CFA, Freund’s Complete Adjuvant; SCI, spinal cord contusion injury; PNL,
partial nerve ligation.
aFor genome-wide expression studies, only miRNAs that were confirmed with an independent method are listed.
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Figure 1. miRNA biosynthetic pathway and tools available for miRNA functional analysis. Primary miRNA (pri-miRNA) transcripts are produced by RNA polymerase II (RNA
pol-II) and processed by the endonuclease Drosha and its cofactors in the nucleus. The resulting hairpin-shaped precursor miRNA (pre-miRNA) is transported to the
cytoplasm via Exportin-5 for further processing by Dicer, an RNase-like enzyme, creating a 21-nucleotide miRNA duplex (miRNA5p–miRNA3p). The mature single-stranded
miRNA is assembled into the miRNA-induced silencing effector complex (RISC). The RISC is then guided by the miRNA to complementary mRNA target sequences. Perfect
sequence complementarity to the target mRNA results in mRNA degradation. Translational repression is initiated in cases of imperfect seed-region pairing. Modes of action
of available tools to study miRNA-mediated functional aspects are also depicted. Lenti- or adeno-associated viral particles carrying pre-miRNA or coding sequences for
either miRNA inhibitors or miRNA sponges are used to circumvent the problems of cellular uptake and to achieve long-term expression. miRNA mimics are synthetic
double-stranded oligos; following cellular uptake one of the strands (the active strand) is incorporated into the RISC and directs downstream mechanisms to downregulate
(See figure legend on the bottom of the next page.)
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responsible for neuropathic pain symptoms [19,20]; there-
fore, analyzing miRNAs in the SDH in different pain
models will elucidate the underlying molecular
mechanisms. Current knowledge of miRNA deregulation
in the SDH is summarized in Table 1.
miRNAs in brain regions involved in pain
Unlike DRGs and the SDH, the specificity and causal
contributions of diverse brain regions and circuits in pain
remain unclear, which is reflected in the low number of
studies that have addressed the role of miRNAs in the
brain in the context of pain pathomechanisms (Table 1).
Poh et al. focused on the prefrontal cortex, which has been
reported to show increased activity concurrent with altered
nociceptive thresholds in animal models [21–23]. By per-
forming miRNA expression profiling on the prefrontal
cortex of a mouse model of carrageenan-induced facial
inflammatory pain, increased expression levels of miR-
155 and miR-223 were observed on day 3, concurrent with
peak mechanical hyperalgesia. Using TaqMan miRNA
expression arrays, Imai et al. studied the potential dereg-
ulation of miRNA over different limbic brain regions 7 days
after partial sciatic nerve ligation. A drastic decrease was
found in the expression of miR-200b and miR-429 in the
nucleus accumbens but not in the hippocampus, frontal
cortex, or amygdala [24].
Tools available to interfere with miRNA expression in
vivo
Tools for antagonizing or attenuating miRNAs
Several chemically modified anti-miRNA oligonucleotides
(AMOs) are in regular use to inhibit endogenous miRNA
expression. AMOs can be targeted against the whole
miRNA sequence, the seed sequence, or the 50 region
[25–27] of the mature miRNA. They contain proprietary
modifications to individual nucleotides (such as 20-O-meth-
yl, 20-O-methoxyethyl, or 20,40-methylene), a mixture of
DNA and Locked Nucleic Acid (LNA), or modifications to
the backbone (such as phosphorothioate linkage). AMOs
are referred to by different names, such as ‘antagomirs’,
‘antimiRs’, and ‘miRNA inhibitors’, depending on the man-
ufacturer, chemistry, and conjugations employed [28,29].
Following cellular uptake, AMOs bind to and sequester the
targeted miRNA and consequently render the miRNA
unavailable for RNA-induced silencing complex (RISC)
incorporation (Figure 1).
Permeation into the nervous system in vivo is a major
challenge for AMO delivery and efficacy. AMOs can be
tagged with a fluorescent dye to enable their visibility
following cellular uptake. Antagomirs are anti-miRNA
sequences conjugated with cholesterol and have been used
in a few studies to inhibit specific miRNA expression in brain
regions following intracerebroventricular (i.c.v.) delivery
[30]. However, these antagomirs proved inefficient in inhi-
biting targeted miRNA in DRGs following intrathecal (i.t.)the mRNA target. The other strand (the passive strand) is degraded. miRNA inhibitors
complementary to either the seed region or the complete sequence of the targeted m
tandem. Following cellular uptake of inhibitors or sponges, the endogenous miRNA i
cleavage or translational repression. miRNA target protectors work at the target mRNA 
binding sites of the target mRNA from the RISC, ultimately resulting in bypass of RISCdelivery [9]. LNA-based miRNA inhibitors have been widely
employed and use of a very short design strategy was found
to enhance their cellular uptake into DRGs following i.t.
delivery [9].
Tools for mimicking miRNA upregulation
‘miRNA mimics’ are double-stranded RNA molecules that
mimic endogenous miRNAs on cellular uptake. The strand
containing the targeted mature miRNA sequence is re-
ferred to as the ‘active strand’ or ‘guide strand’ and the
other as the ‘inactive strand’ or ‘passive strand’. The active
strand is preferentially incorporated into the RISC, where-
as the passive strand is degraded (Figure 1). Several
proprietary chemical modifications have been applied to
promote preferential integration of the guide strand into
the RISC. Conjugating cholesterol to the passive strand
can facilitate cellular uptake and simultaneous conjuga-
tion of fluorescein isothiocyanate (FITC) to the active
strand can facilitate localization following uptake in pe-
ripheral sensory neurons [9].
Transgenic approaches with miRNA
In addition to the widely used miRNA mimics and inhibi-
tors, viruses engineered to encode sequences for either
inhibitor or precursor miRNA (pre-miRNA) sequences
have also been utilized. Another approach for studying
miRNA function is to generate transgenic mice lacking
specific miRNA genes. Although global knockout of the
miRNA-processing enzymes Dicer, Drosha, or Argo is em-
bryonically lethal [31], mice with sensory neuron-specific
deletion of Dicer have been generated [32]. However, be-
cause all miRNAs are affected on deletion of Dicer, little
can be inferred about the biological functions of individual
miRNAs from this approach, not least because diverse
miRNAs have distinct and, at times, mutually opposing
modulatory effects on pain. A genome-wide miRNA knock-
out resource covering many of the known mouse miRNA
genes is available in the form of embryonic stem (ES) cell
repositories [33] and utilizing this resource to generate
knockout allelic lines for specific miRNAs constitutes an
approach that can be exploited to study the functions of
individual miRNAs.
Unlike other organ systems, a typical problem faced
while performing research on the nervous system, and in
pain research in particular, is getting miRNA inhibitors
and mimics into the target tissue. This is a particular
challenge in the SDH and DRG. Researchers have
employed varied approaches to deliver miRNA inhibitors
or mimics into neuronal tissue, such as direct injection into
the brain/spinal cord parenchyma or delivery to the corre-
sponding compartments of the cerebrospinal fluid via i.c.v.
or i.t. injection; i.t. delivery of miRNA inhibitors together
with a chemical reagent to modulate specific miRNA ex-
pression in the SDH or DRG has been employed to inves-
tigate the phenotypic effects of miRNA gain or loss of
function on pain [9,34]. Low-dose delivery of miRNA are single-stranded chemically modified oligonucleotides containing a sequence
iRNA. miRNA sponges are also like inhibitors but contain multiple sequences in
s scavenged and cannot be incorporated into the RISC and contribute to mRNA
level. Following cellular uptake, the target protectors bind to and block the miRNA-
-associated mRNA cleavage or translational repression.
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Box 1. miRNAs at the interface between sensory neurons
and non-neuronal cells
Interactions between nociceptive neurons, immune cells, and
microglia in the periphery and spinal cord are known to have a
critical role in modulating nociceptive sensitivity [92]. Some studies
have initiated analyses of the involvement of miRNAs in this
context. For instance, reduced miR-124 levels in spinal microglia
have been linked to the transition from acute to persistent pain
states [57]. Peripheral immune contributions have also been
studied. In a mouse peritonitis model of self-limited acute
inflammatory exudates, a set of miRNAs – namely, miR-21, miR-
146b, miR-208a, miR-203, miR-142, miR-302d, and miR-219 – were
selectively regulated [93]. miR-146a is overexpressed in the cartilage
of OA patients [94], in the synovial tissue of rheumatoid arthritis
(RA) patients [95], and in human monocytic cell lines following
lipopolysaccharide or proinflammatory stimuli [96] and this over-
expression has been shown to be important in the manifestation of
OA pain in knee joints [84,85]. Further studies are required to
develop a clearer picture of the functional roles exerted by miRNAs
at the neuron–immune cell interphase.
miRNA deregulation has also been reported in several other pain
conditions. For instance, miR-199a-5p has been implicated in bladder
pain syndrome [97] and increased expression of miRNA-449b and
miRNA-500 has been reported in the bladder smooth muscle cells of
patients with bladder pain syndrome [98]. miRNA profiles from
human blood samples have been suggested as potential biomarkers
for the prediction of complex regional pain syndrome (CRPS) [99].
miR-203 is downregulated in paw keratinocytes following skin
incision and reciprocal regulation of one of its target genes,
phospholipase A2 activating protein (PLAA), has been observed [100].
Review Trends in Molecular Medicine August 2014, Vol. 20, No. 8mimics/inhibitors is sufficient to considerably enrich the
reagents in DRGs without affecting the spinal cord, which
would be an advantage when targeting peripheral sensory
mechanisms specifically [9]. A recent study reported pref-
erential uptake of miRNA inhibitors and mimics by SDH
neurons following intravenous delivery [35], which is more
amenable for clinical translation, but this must be tem-
pered by the wide-scale side effects one would expect at the
systemic level.
Although these recently reported approaches give sat-
isfactory results, there is a clear need to develop better
methods for delivery of miRNA inhibitors or mimics into
sensory neurons. For instance, inorganic nanoparticles
such as gold and silicon oxide have been used to deliver
miRNA expression modulators into different cellular sys-
tems in vitro [36–38] and in vivo via systemic delivery [39–
42]. Specific targeting of rabies virus glycoprotein (RVG)-
directed disulfide polyethylenimine (SSPEI)-mediated de-
livery of miRNA-124 into the brain following systemic
administration has been reported [43]. Adapting these
strategies to achieve sensory neuron-specific delivery will
have enormous potential for future studies.
miRNA ‘sponges’ containing multiple tandem binding
sites for a given miRNA have been reported [44] and can
be used to inhibit individual miRNAs or a family of miRNAs
containing the same seed region both in vitro and in vivo
[45–47]. Furthermore, the use of adenovirus, lentivirus, or
herpes simplex virus (HSV) engineered to encode miRNA
inhibitors, pre-miRNAs, or miRNA sponges presents anoth-
er viable and attractive alternative for in vivo modulation of
miRNA expression. Given the proven success of direct
delivery of virions into the SDH or DRG or by i.t. means
[48,49] in knocking down specific genes, this approach
has direct applicability for pain research. An advantage of442using virions is that a single injection can lead to expression
of the corresponding miRNA inhibitor or pre-miRNA over
months. By contrast, when injected directly, mimics and
inhibitors need to be replenished every 24 h [9].
Predicting and validating targets of miRNAs
A challenging step in understanding miRNA function is
identifying the molecular mechanisms of miRNA action
that underlie a specific phenotype. This is closely associat-
ed with the identity and function of the mRNAs that are
targeted specifically by individual miRNAs. Several
miRNA target-prediction algorithms have been developed
and are available for both offline and online use, such as
TargetScan and Pictar (reviewed in [50,51]). Each predic-
tion algorithm has its own merits and effective parameters
to predict miRNA–mRNA binding and delivers numerous
predicted genes for every miRNA, making it impossible to
evaluate miRNA–mRNA functional pairs systematically in
an unbiased approach; this is compounded by the fact that
one miRNA can control the expression of several mRNAs
simultaneously. Diverse approaches have been employed
to circumvent this problem. One approach is based on
increasing the mRNA target-prediction stringency by
employing several prediction algorithms in parallel and
choosing those targets that are consistently predicted by
several algorithms. Although this approach is not
completely foolproof, it increases the confidence of the
predicted target. Another approach frequently used is to
follow a system-level analysis to identify the probable
functions that could be affected by the miRNA. Although
this approach could provide a broader picture of miRNA-
mediated pathways, it is less useful for indicating a specific
molecular interaction. Finally, one approach that directly
reveals the validity of the predicted miRNA–mRNA pairs
is to treat cells or in vivo tissue with mimics or inhibitors of
the dysregulated miRNAs, extract the affected tissues, and
perform expression analyses directly on the predicted
mRNA targets. If a miRNA mimic consistently represses
expression of a target gene whereas the corresponding
miRNA inhibitor enhances target gene expression, that
can be indicative of the validity and specificity of the
miRNA–mRNA pairing.
Several approaches have been implemented to validate
functional interactions between questionable miRNA and
mRNA pairings. For instance, reporter constructs carrying
the binding site of putative mRNA under the control of a
reporter promoter have been used extensively [9,34]. Al-
though this approach confirms the functional interaction of
a given miRNA–mRNA pair, it mostly relies on a heterolo-
gous in vitro system and is difficult to perform in vivo.
Alternatively, single-stranded modified RNA oligos that spe-
cifically block the interaction of a given miRNA with a target
mRNA (referred to as miRNA target protectors, see Figure 1)
have been used [52–54] in vitro and in easily accessible model
organisms such as zebrafish. Recently, vector-based target
protectors have been developed, which may have wide appli-
cations in miRNA target identification [55].
Functional insights into miRNAs in pain modulation
Although many studies have addressed miRNA deregulation
along the somatosensory nociceptive pathway, relatively few
Review Trends in Molecular Medicine August 2014, Vol. 20, No. 8have investigated miRNA-mediated molecular processes
leading to nociceptive modulation. One study reported sev-
eral presumably sensory neuron-specific miRNAs following
the sensory neuron-specific deletion of Dicer [32], whereas
another study highlighted the importance of Dicer-depen-
dent mechanisms in sciatic nerve regeneration in vivo and in
vitro [56]. Sensory neuron-specific deletion of Dicer does not
lead to sensory neuronal loss or deficits in acute pain, butmiRNA 
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Almost all of the studies on miRNA function and mRNA
target identification reported here took the candidate-gene
approach to identify genes with binding sites in their 30
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dulation along the somatosensory pain pathway. miRNA–mRNA functional pairs
pinal cord dorsal horn (SDH), and brain are represented. mRNA targets that are
443
Review Trends in Molecular Medicine August 2014, Vol. 20, No. 8has binding sites in the 30 UTR of all three subunits and
can regulate their expression without affecting their traf-
ficking properties [34]. It was also reported that inhibition
of miR-103 in the SDH can induce partial but significant
hyperalgesia in naı¨ve mice and that overexpression of miR-
103 protects mice from SNL-induced mechanical and cold
hyperalgesia [34]. This was the first report on the modula-
tion of nociceptive sensitivity via a single miRNA.
Additional functional studies have shown that restor-
ing miR-124 levels in spinal microglia reverses carrageen-
an-induced thermal hyperalgesia in naı¨ve mice and
SNL-induced mechanical allodynia in neuropathic mice
[57]. Restoring miR-7a levels in the DRG neurons of
neuropathic mice suppresses established neuropathic
hyperalgesia and miR-7a exerts these antinociceptive
effects by regulating expression of the b2 subunit of the
voltage-gated sodium channel (Scn2b) [58]. The miRNA
let-7 is shown to have a role in the development of toler-
ance to morphine-induced analgesia [59]. miR-21 has been
shown to be functionally relevant in axonal outgrowth [60]
and neuropathy-induced mechanical hyperalgesia [61].
Restoration of miR-96 or miR-183 via i.t. delivery of the
miR-96 mimic or lentivirions carrying miR-183, respec-
tively, alleviates neuropathic hyperalgesia. One of their
target genes, the sodium channel voltage-gated type III
alpha (Nav1.3), is inversely regulated [15,62]. In contrast
to the candidate approaches described above, only one
comprehensive and unbiased study to understand
miRNA-mediated nociceptive mechanisms in peripheral
sensory neurons followed by functional and mechanistic
analyses has been reported to date [9].RNA decoy
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can lead to chromatin remodelling [102,106]. Some other lncRNAs result in the gene
cleavage in the cytoplasm and thus inhibit target mRNA expression. Some lncRNAs
repression, transcriptional activation, modulation of splicing patterns, or degradation [
444Very few studies have addressed miRNA targets in the
brain in the context of nociceptive mechanisms and these
have been restricted to reporting only inverse regulation of
one of the predicted target genes. One study reported
inverse regulation of miR-155 and one of its predicted
targets, CCAAT/enhancer binding protein Beta (c/ebp-b),
in the prefrontal cortex in a facial inflammatory pain model
[23]. Another study reported inverse regulation of miR-
200b/miR-429 and DNA methyltransferase 3a (DNMT3a)
in the nucleus accumbens in a sciatic nerve ligation model
of neuropathic pain [24] (Figure 2).
lncRNAs in pain processing
Unlike miRNAs, lncRNA sequences (with nucleotide
lengths >200) [63,64] have barely been studied in pain
states. lncRNAs are known to act in both cis and trans, with
both nuclear and cytoplasmic localization being reported
[65,66]. lncRNAs are categorized into four distinct types
depending on their location in the genome with respect to
protein-coding genes: exonic, intronic, overlapping, and
intergenic. The intergenic lncRNAs, often referred to as
lincRNAs, have received special attention owing to grow-
ing evidence for their involvement in cancer pathophysiol-
ogy and chromatin structure. Several modes of action have
been shown for lncRNAs, such as interfering with tran-
scription, post-transcriptional processing, chromatin
remodeling, and generating small ncRNAs (Figure 3).
lncRNAs have been shown to be functionally important
for several developmental events, such as X chromosome
inactivation [67]. Recent reports indicate that more than
50% of the over 10 000 lncRNAs reported are expressed inlncRNA
endo-siRNAs
Direct
processing of
target mRNAs
Translaonal
inhibion
Modulaon of
splicing paernsegradaon
ted  cleavage
TRENDS in Molecular Medicine
ve described different modes of action for the functioning of lncRNAs in different
and genomic position with respect to coding genes (intragenic, exonic, intronic, or
 decoys at the genetic level by directly scavenging transcription factors [101,102].
cavenging miRNA functional effectors and thereby limiting miRNA availability for
3–105]. Some lncRNAs act as ‘RNA scaffolds’ for regulatory protein binding, which
ration of endogenous small interfering RNAs (endo-siRNAs) via Dicer-mediated
 are known directly to modulate target mRNA expression levels by translational
107–109].
Box 2. lncRNA-mediated regulation of neuropathic pain
Unlike the well-studied miRNAs in the context of chronic pain, only
one study has addressed a potential role for lncRNAs in neuropathic
pain modulation. Zhao et al. reported that SNL resulted in increased
expression of Kcna2 asRNA in DRGs ipsilateral to the nerve injury,
whereas the expression of Kcna2 mRNA and proteins showed a
corresponding decrease [74]. They further identified a binding motif
for the transcriptional activator myeloid zinc-finger protein 1 (MZF1)
in the promoter region of Kcna2 asRNA and showed that it controls
the expression of Kcna2 asRNA, Kcna2 mRNA, and the Kcna2
protein. Further investigation revealed that the expression of Kcna2
asRNA is triggered by MZF1 under neuropathic conditions. Finally,
overexpressing or blocking Kcna2 asRNA in DRGs in vivo led to
alleviated or attenuated neuropathy-induced mechanical, cold, and
thermal sensitivity in rats. This report provides proof of principle
that the study of lncRNAs holds tremendous potential in under-
standing chronic pain.
Review Trends in Molecular Medicine August 2014, Vol. 20, No. 8the CNS [68,69], suggesting a prominent functional role.
Consistent with this observation, several studies have
documented the functional importance of lncRNAs in brain
disorders, such as Alzheimer’s disease, and in brain tumors
and neurodevelopmental disorders [70–72]. Genome-wide
screens have reported strong expression and dysregulation
of a subset of lncRNAs in DRGs following sciatic nerve
injury and one of these, the lncRNA BC089918, has been
shown to have an influential effect on neurite outgrowth in
vitro [73]. To date only one study has addressed a lncRNA
associated with nociceptive modulation and elucidated its
function [74], identifying a novel antisense lncRNA for the
potassium channel Kcna2 in DRG neurons; namely, Kcna2
antisense RNA (asRNA) (Box 2).
piRNAs as potential mediators of nociceptive
mechanisms
piRNAs constitute another type of endogenous ncRNA that
may play a functional role in pain modulation. piRNAs are
longer (26–31 nucleotides) than miRNAs (21–24 nucleo-
tides) and represent the largest class of ncRNAs in animal
cells. piRNA biogenesis is Dicer independent and piRNAs
do not interact with Argonaute 2, a key enzyme in the
RNAi pathway, making them distinct from miRNAs in
both biogenesis and function. piRNAs were hitherto be-
lieved to have functional roles in germline development
and adult reproductive organs only. However, recent deep-
sequencing studies have identified an enriched pool of
piRNAs in the mouse hippocampus [75], suggestive of
neuronal function. Furthermore, a functional role of the
piRNA piR-F has been reported in memory-related synap-
tic plasticity in Aplysia, where it functions by silencing a
memory-repressing transcription factor, CREBB2 [76].
Considering the overlapping functions of several known
genes involved in hippocampal synaptic plasticity and
chronic pain development, as well as the enriched pool
of piRNAs in the CNS and their role in synaptic plasticity,
further study of piRNAs may provide great insights for
pain scientists.
ncRNAs as therapeutic targets for the treatment of
chronic pain
Because it has now been shown in preclinical animal
studies that modulation of the expression of a singlemiRNA can relieve different types of chronic pain condi-
tions, developing miRNA-based therapies for the treat-
ment of chronic pain may be possible. However, a
primary bottleneck is delineating the peripheral and cen-
tral mechanisms and contributions of the miRNA-mediat-
ed changes that lead to chronic pain. This is especially
challenging given the broad expression of many known
miRNAs.
The second and most important challenge is to develop
noninvasive means of delivering miRNA modulators, such
as AMOs or mimics, into DRGs, the brain, and/or the SDH
without significant off-target effects. There have been a few
breakthroughs in this direction in other organ systems in
the recent past; however, developing ncRNA-based thera-
pies for pain treatment remains a challenge because the
nervous system is still a formidable venue for manipula-
tions. Nonetheless, several new studies provide advances
and hope. For instance, a subcutaneous antisense inhibitor
of miR-122 has been successfully tested in Phase II clinical
trials against hepatitis C virus (HCV) infection in humans
[77]. Another study reported the efficacy of subcutaneous
asRNA delivery in inhibiting miRNA-33 family members
in nonhuman primates [78]. Intravenous delivery of lipo-
some injectable substances containing a miRNA34 mimic
for liver cancer treatment are in Phase I clinical trials
(http://clinicaltrials.gov/ct2/show/NCT01829971). Taking
clues from these studies and developing them to deliver
miRNA modulators to peripheral or central sensory neu-
rons will help in the development of new pain therapies.
Concluding remarks and future perspectives
ncRNAs play a functional role in the modulation of noci-
ceptive sensitization and recent studies implicate them as
promising therapeutic targets for the treatment of chronic
pain. Although reliable tools are available to investigate
the expression and regulation of miRNAs along nociceptive
pathways, the elucidation of miRNA-mediated functional
and mechanistic aspects in the context of pain remains a
bottleneck. Importantly, the development of unbiased
approaches to investigate gene targets for individual miR-
NAs is required, with help from miRNA sensors, decoy
libraries, and high-throughput sequencing of RNA isolated
by crosslinking immunoprecipitation (HITS-CLIP). The
development of sensory neuron-specific and ncRNA-specif-
ic transgenic animal lines is another important direction
that deserves attention. Other ncRNAs, such as lncRNAs
and piRNAs, are promising new avenues to explore in the
context of pain. Given their tremendous therapeutic po-
tential, it will be important to understand the role of
ncRNAs in regulating protein homeostasis across the cel-
lular and systemic domains (Box 3).
Although understanding the mechanisms of action of
ncRNAs in pain modulation is important, improving their
‘druggability’ in terms of modification of their in vivo
delivery, bioavailability, efficacy, and safety is a branch
of ncRNA research that should advance in parallel with
mechanistic analysis. This is a field characterized by chal-
lenges and pitfalls, but also by tremendous promise for the
understanding and treatment of pathological pain. The
coming years will reveal whether ncRNAs live up to the
immense promise they hold in biology and disease.445
Box 3. Outstanding questions
 What is the specificity of ncRNA expression and dysregulation at
distinct avenues of the somatosensory nociceptive pathway in
different chronic pain conditions?
 How do different ncRNAs and their target proteins interact in
chronic pain?
 What are the functional contributions of ncRNAs in modulating
chronic pain and the underlying molecular and circuit-based
mechanisms?
 What is the interplay between diverse ncRNA species in
orchestrating gene expression and modulating the induction
and maintenance of chronic pain?
 Most studies on pain are targeted toward miRNAs, but what are
the potential roles of lncRNAs and piRNAs in the modulation of
pain?
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